Pharmacoeconomics of antimicrobial therapy

American Journal of Health-System Pharmacy

Volumn 56, Issue 22 SUPPL. 3, 1999, Pages

  Paladino, Joseph A ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b Millard Fillmore Suburban Hospital   (United States)

Author keywords

Anti infective agents; Costs; Dosage schedules; Drug administration routes; Pharmacodynamics; Pharmacoeconomics; Pharmacokinetics; Quinolones; Respira tory tract infections; Substitution

Indexed keywords

ANTIINFECTIVE AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; CONFERENCE PAPER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION;

EID: 0033571657     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.suppl_3.s25     Document Type: Conference Paper

References (31)

1. Townsend RJ. Postmarketing drug research and development. Drug Intell Clin Pharm. 1987; 21:134-6.
2. Cooke J. The practical impact of pharmacoeconomics on institutional managers. Pharmacoeconomics. 1994; 6:289-97.
3. Woodward RS, Medoff G, Smith MD et al. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Am J Med. 1987; 83:817-23.
4. Rifenburg RP, Paladino JA, Hanson SC et al. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am J Health-Syst Pharm. 1996; 53:2054-62.
5. Nicolau DP, White RL, Friedrich LV et al. The costs of burn care: an analysis with an emphasis on the use of parenteral antimicrobials. J Burn Care Rehabil. 1994; 15:244-50.
6. McKinnon PS, Paladino JA, Grayson ML et al. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1997; 24:57-63.
7. Friedrich LV, White RL, Kays MB et al. Pharmacoeconomic evaluation of treatment of penetrating abdominal trauma. Am J Hosp Pharm. 1992; 49:590-4.
8. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III data files. Washington, DC: U.S. Department of Health and Human Services; 1995.
9. Niederman MS, McCombs JS, Unger AN et al. The cost of treating community-acquired pneumonia. Clin Ther. 1998; 20:820-37.
10. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP Ann Pharmacother. 1991; 25:1050-7.
11. Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993; 37:1073-81.
12. Hyatt JM, McKinnon PS, Zimmer GS et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet. 1995; 28:143-60.
13. Nix DE, Sands MF, Peloquin CA et al. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Am J Med. 1987; 82:352-6.
14. Paladino JA, Fell RE. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother. 1994; 28:384-9.
15. Dudley MN, Mandler HD, Gilbert D et al. Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model. Am J Med. 1987; 82:363-8.
16. Schentag JJ, Smith IL, Swanson DJ et al. Role for dual individualization with cefmenoxime. Am J Med. 1984; 77:43-50.
17. Luzier A, Goss TF, Cumbo TJ et al. Mathematical examination of dual individualization principles (III): development of a scoring system for pneumonia staging and quantitation of response to antibiotics: results in cefmenoxime-treated patients. Ann Pharmacother. 1992; 26:1358-65.
18. Goss TF, Forrest A, Nix DE et al. Mathematical examination of dual individualization principles (II): the rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother. 1994; 28:863-8.
19. Goss T, Griffiths RI, Fekete T et al. A decision model to evaluate the costs and outcomes of alternative treatments for Enterococcus faecium bloodstream infections. Paper presented at 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; 1998 Sep 24-27.
20. Linden P, Paladino J, Saul M et al. The economic impact of bacteremia due to vancomycin-resistant Enterococcus faecium: a case-control study. Paper presented at 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; 1998 Sep 24-27.
21. Thomas JK, Forrest A, Bhavnani SM et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998; 42:521-7.
22. Paladino JA. How should we evaluate new anti-infectives for respiratory tract infections? Can Respir J. 1999; 6(suppl A): 31A-4A.
23. Schentag J, Carr JR, Adelman MH et al. Formulary management vs disease management. Infect Dis Clin Pract. 1996; 5:1-6.
24. Carr JR, Fitzpatrick P, Izzo JL et al. Changing the infection control paradigm from off-line to real time: the experience at Millard Fillmore Health System. Infect Control Hosp Epidemiol. 1997; 18:255-9.
25. Quintiliani R, Cooper BW, Briceland LL et al. Economic impact of streamlining antibiotic administration. Am J Med. 1987; 82:391-4.
26. Hitt CM, Nightingale CH, Quintiliani R et al. Streamlining antimicrobial therapy for lower respiratory tract infections. Clin Infect Dis. 1997; 24(suppl 2):S231-7.
27. Paladino JA, Sperry HE, Backes JM et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med. 1991; 91:462-70.
28. Partsch DJ, Paladino JA. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy. Ann Pharmacother. 1997; 31:1137-45.
29. Omidvari K, de Boisblanc BP, Karam G et al. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med. 1998; 92:1032-9.
30. Cooke J. Cost issues in sequential therapy. J Infect. 1998; 37 (suppl 1):45-50.
31. File TM, Segreti J, Dunbar L et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/ or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997; 41:1965-72.